News | Neuro Imaging | July 05, 2019

Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden

Clinical data shows Delta T1 maps from Imaging Biometrics on par with central reader analysis but offer substantial time and cost savings

Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden

July 5, 2019 — Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American Journal of Neuroradiology1 confirming the value of IB’s dT1 maps in streamlining routine radiology workflows and multi-center clinical trials.

The study confirms the value of IB’s dT1 maps in streamlining routine radiology workflows and multi-center clinical trials.

Objective, accurate and reproducible methods to measure brain tumor volumes are important in the assessment of treatment response. Contrast-enhanced magnetic resonance imaging (MRI) is the most common approach to monitor treatment, but it is highly variable and confounded by numerous factors including differences in vendor platforms, field strengths and general MRI system instabilities. It is well-acknowledged that these factors contribute to the large disagreement of up to 50-60 percent between neuroradiologists when assessing tumor burden and evaluating treatment response.

Quantitative dT1 maps offer an elegant and automated solution that overcome these challenges and, therefore, have the potential to cause a disruptive shift in how brain tumor burden is assessed. dT1 maps compare calibrated pre- (T1) and post-contrast (T1+C) anatomic images. The calibration process, exclusive to IB, translates the relative and variable MR intensity values to a fixed and consistent scale. This built-in step is independent of scanner platform, field strength and time point, and has been shown superior over manual tissue normalization algorithms.

The secondary analysis of multicenter clinical trial data was performed by lead author Kathleen Schmainda, Ph.D., from the Medical College of Wisconsin, and colleagues. In total, 123 patients from 23 institutions enrolled in the study. The study compared IB’s dT1 maps to two primary readers and one adjudicator to manually delineate enhancing lesions. The results proved the dT1 method to be comparable to expert reads for determining early tumor progression and proved superior for further distinguishing treatment responders from non-responders at the week 8 time point. Another key outcome of the study was that only the dT1 method could predict differences in outcomes at the week 8 time point.\

For more information: www.imagingbiometrics.com

 

Reference

1. Schmainda K.M., Prah M.A., Zhang Z., et al. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. American Journal of Neuroradiology, June 27, 2019. doi: 10.3174/ajnr.A6110

Related Content

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution
News | Magnetic Resonance Imaging (MRI) | July 05, 2019
Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...